3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
36
Neoplasms
7
Neoplasm Metastasis
7
Endometrial Neoplasms
7
Ovarian Neoplasms
5
Triple Negative Breast Neoplasms
4
Breast Diseases
3
Brain Neoplasms
3
Sarcoma
2
Neoplasms by Site
2
Meningioma
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor, Adult
1
Sarcoma, Kaposi
1
Retinoblastoma
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Osteosarcoma
1
Neurofibromatosis 1
1
Neoplasm, Residual
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Interventions
Cisplatin
23
pembrolizumab
21
Carboplatin
13
Paclitaxel
12
Radiotherapy
11
Brachytherapy
11
Drug Therapy
10
Bevacizumab
10
Blood Specimen Collection
7
Injections
6
Colposcopy
6
Specimen Handling
5
toripalimab
4
Taxes
4
Surveys and Questionnaires
4
Nivolumab
4
Mass Screening
4
Human Papillomavirus DNA Tests
4
Gemcitabine
4
Chemotherapy, Adjuvant
4
Chemoradiotherapy
4
spartalizumab
3
lenvatinib
3
camrelizumab
3
aldesleukin
3
Restraint, Physical
3
Radiation
3
Fulvestrant
3
Cyclophosphamide
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uterine Cervical Neoplasms
×
abemaciclib
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled